Drug Patent Watch

DECEMBER 9, 2024

In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”

Drugs

Broad Institute

JULY 29, 2025

Related groups OASIS Consortium Carpenter-Singh Lab Health and Environment Sciences Institute (HESI) Related news A marriage of microscopy and machine learning Roughly a third of drug candidates fail in the first phase of clinical trials, often due to unanticipated toxic effects that weren’t apparent in animal tests.

Animal Testing

PPD

OCTOBER 31, 2024

As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. From adapting to complex new trial designs to embracing cutting-edge technologies, staying ahead requires a deep understanding of the current landscape.

Drug Development

The Pharma Data

JULY 2, 2025

Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical trial of ART-123, a recombinant human thrombomodulin (rTM), in Japan. Source link

Trials

The Pharma Data

JUNE 18, 2025

The IDeate-Prostate01 trial marks a significant advancement in the B7-H3 ADC development program and underscores the shared commitment of both companies to addressing difficult-to-treat cancers. Study Design and Objectives The Phase 3 IDeate-Prostate01 study is a randomized, multicenter, open-label clinical trial.

Trials

Drug Target Review

JUNE 11, 2025

Clinical genomics, powered by NGS, enables more precise target validation, improved patient stratification and optimised trial design, ultimately aiming to increase PoS. If it’s not mixable, the data value chain (from R&D phase to production phase) is neither interpretable or reproducible. Highlighting data integration.

Drugs

PPD

NOVEMBER 11, 2024

By accelerating timelines, anticipating challenges and alleviating bottlenecks, pharmaceutical companies and combined CDMO and CRO partners together can help ensure those potential treatments reach the patients who need them as efficiently as possible.

Drug Development

Drug Target Review

JUNE 9, 2025

A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis.

Disease

Drug Target Review

OCTOBER 30, 2024

Now take a step further: envision testing drugs in these organoids to identify the ones that can treat disease safely and effectively without needing to run expensive clinical trials first. Creating replicas of organs in vitro has been a goal of researchers for over a century.

Treatment

Drug Target Review

JULY 7, 2025

Their unique suitability has made them valuable for evaluating pharmacokinetics, toxicology and safety in drug candidates before human clinical trials. Animal rights groups, policymakers and the public are increasingly vocal in opposing their use in research, with litigation and regulatory interventions intensifying in recent years.

Drug Research

The Pharma Data

JUNE 23, 2025

Phase 2 Study: Transformative Weight Loss and Glycemic Control The Phase 2 trial focused on evaluating the efficacy and safety of MariTide in individuals with obesity, both with and without Type 2 diabetes (T2D). Executive Vice President of Research and Development at Amgen, emphasized the broader implications of these findings.

Trials

Drug Target Review

JUNE 6, 2025

This dual role enables him to bridge research and clinical practice, ensuring scientific innovation is directly informed by patient care. “As Delpassand’s clinical experience plays a key role in shaping the research pipeline. This is where the SPICA Center comes in. “The The SPICA Center was built to address this gap.”

Therapies

The Pharma Data

JUNE 6, 2025

Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co., in collaboration with Otsuka Pharmaceutical Co.,

Trials

Drug Target Review

JULY 21, 2025

Current challenges in CNS drug development Drug development for the CNS is particularly challenging and researchers face several hurdles to producing effective and safe treatments, many of which are unique to the CNS. These gaps in knowledge can lead to a trial-and-error approach to clinical trials, which can result in high failure rates.

Drug Development

The Pharma Data

JUNE 13, 2025

Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. MRI) and Astellas Pharma Inc.

Research

Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. Because LLMs are trained on extensive, internet-scale datasets, they can learn to identify contexts linking words and language.

Drug Development

Drug Target Review

FEBRUARY 10, 2025

In just two years, CTMC has advanced eight therapies into clinical trials, harnessing genetic engineering to enhance T-cell effectiveness in the fight against cancer. His approach focused on integrating key components of the process: research, clinical, regulatory, and manufacturing into a cohesive, unified system.

Therapies

The Pharma Data

AUGUST 1, 2025

This partnership brings together Altasciences’ extensive expertise in preclinical research and early clinical development with VoxCell’s groundbreaking tissue engineering technology, promising to deliver a more human-relevant, predictive, and efficient drug development paradigm.

Drug Development

Alta Sciences

JULY 31, 2025

Altasciences shares this forward-thinking approach, and we’re excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.” Julie-Ann Cabana Altasciences jcabana@altasciences.com Weight 13 Tags Preclinical Research To learn more about Altasciences, visit altasciences.com.

Drug Development

Conversations in Drug Development Trends

OCTOBER 29, 2024

By: Juliane Mills, Senior Director, Therapeutic Strategy Lead, Rare Disease The rise of patient-led clinical research, particularly in rare disease, represents a significant shift in the clinical trial landscape. Why Is There an Increase in Patient-Led Rare Disease Research?

Clinical Research

Drug Target Review

JULY 29, 2025

Effective financial management is a cornerstone in the success of clinical trials, which are integral to the advancement of drug discovery. As the pharmaceutical and biotech industries continue to evolve, clinical trials become more complex, and the importance of robust financial oversight has never been clearer.

Clinical Trials

The Pharma Data

JUNE 25, 2025

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA

Drug Target Review

DECEMBER 16, 2024

Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drug development. In addition to this, I also chaired national trials evaluating an anti-GD2 antibody in pediatric osteosarcoma.

Medical Schools

Drug Target Review

NOVEMBER 25, 2024

I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development. At this point, I knew that I wanted to join the biotech and pharmaceutical industry, so I moved to a small biotech company in London, where I spent three to four years learning the fundamentals of the biotech industry.

Treatment

Drug Target Review

DECEMBER 11, 2024

As a contract research organisation, we have supported numerous clients in overcoming matrix interference, particularly small and emerging biotherapeutics developers who may lack the in-house expertise to navigate such complex problems. This highlights its vital role in modern biotherapeutic research.

International

Drug Target Review

AUGUST 6, 2025

A validated target in cardiovascular disease, new research from Esperion Therapeutics suggests that ACLY could also play a role in liver disease – specifically, primary sclerosing cholangitis (PSC). The team is also focused on developing robust biomarkers to measure ACLY inhibition and its downstream effects in future trials.

Therapies

The Pharma Data

JUNE 9, 2025

Cardiovascular Insights from the XYLO Trial One of the most notable late-breaking presentations was the Phase 4 XYLO study, which examined the cardiovascular benefits of switching patients from high-sodium, twice-nightly oxybate therapy to the same dosage of low-sodium Xywav over a six-week period. The average decrease was −4.1

FDA Approval

PPD

DECEMBER 16, 2024

The drug development industry faces rising costs and increasingly complex protocols as top challenges, with 49% of developers citing costs as their primary concern and 39% pointing to protocol complexity as a key hurdle, according to a recent survey of 150 drug developers worldwide by the PPD clinical research business of Thermo Fisher Scientific.

Drug Development

Drug Target Review

JULY 18, 2025

With over two decades of experience in biomedical research, he is leading efforts to translate breakthrough GPCR biology into differentiated therapeutic strategies that can overcome immune resistance and offer new hope to patients with limited treatment options. This strategy is exemplified by its flagship programme: DT-7012.

Medical Chemistry

Broad Institute

NOVEMBER 25, 2024

Ladders to Cures (L2C) Accelerator By Maria Nemchuk November 25, 2024 Breadcrumb Home Ladders to Cures (L2C) Accelerator The Ladders to Cures (L2C) Accelerator aims to catalyze progress across the research ecosystem and accelerates advances leading to treatments and cures for patients with rare genetic diseases. Visit broad.io/L2C2023

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 8, 2025

Multiple deals have been struck by large companies such as Roche and Novartis, suggesting pharmaceutical firms believe degraders have only begun to show their promise. The result of their research is what’s now described as targeted protein degradation, which conceptually is a bit like ordering a junk hauling service for the cell.

Targeted Protein Degradation

Alta Sciences

JUNE 6, 2025

For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. Tags Bioanalysis Preclinical Research Weight 15

Pharmacokinetics

New Drug Approvals

JULY 19, 2025

3] [4] A prodrug of contezolid, contezolid acefosamil, which is formulated for IV administration [5] is in Phase III clinical trials for diabetic foot infection. [6] 3] [4] A prodrug of contezolid, contezolid acefosamil, which is formulated for IV administration [5] is in Phase III clinical trials for diabetic foot infection. [6]

Clinical Trials

The Pharma Data

JUNE 24, 2025

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

Pharma R&D

The Pharma Data

JUNE 24, 2025

This dual-pronged approach allows Revolution Medicines to access capital tailored to its evolving needs without relinquishing equity or ceding commercial rights to a larger pharmaceutical partner. Early data has demonstrated encouraging signs of efficacy and safety, and the company is planning to initiate pivotal trials in the near term.

Drug Development

Alta Sciences

MARCH 4, 2025

The CCALC is a grassroots organization that was founded by several pharmaceutical industry members seeking clarity around the conduct of abuse and dependence potential assessments for novel drugs in development. This was in 2006, at a time when the FDA guidances on these topics had not yet been published.

Clinical Trials

The Pharma Data

AUGUST 3, 2025

The five-year results were derived from the Phase III Portal study, a long-term extension of the pivotal Archway trial, and presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting held in Long Beach, California. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. Source Link

Treatment